We are live on
!
Find out more
ECM
ExodusPoint Capital Management Portfolio holdings
AUM
$12.6B
1-Year Est. Return
30.13%
This Fund
S&P 500
This Quarter
Est. Return
+4.88%
1 Year Est. Return
+30.13%
3 Year Est. Return
+85.63%
5 Year Est. Return
+104.04%
10 Year Est. Return
–
AUM
$12.7B
AUM Growth
+$2.96B
(+30%)
Cap. Flow
+$2.85B
Cap. Flow
% of AUM
22.37%
Top 10 Holdings %
Top 10 Hldgs %
30.34%
Holding
2,189
New
723
Increased
409
Reduced
328
Closed
716
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$689M |
| 2 |
Broadcom
AVGO
|
+$153M |
| 3 |
Walmart Inc
WMT
|
+$136M |
| 4 |
Amazon
AMZN
|
+$104M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$71.5M |
| 2 |
Pinnacle West Capital
PNW
|
+$49.1M |
| 3 |
Procter & Gamble
PG
|
+$43.7M |
| 4 |
Chevron
CVX
|
+$43.1M |
| 5 |
Hershey
HSY
|
+$43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.62% |
| 2 | Healthcare | 9.42% |
| 3 | Industrials | 7.55% |
| 4 | Financials | 6.82% |
| 5 | Consumer Discretionary | 6.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Terex
TEX
$7.58B
| $316K | ﹤0.01% |
+5,913
| New | +$299K |
|
1302
Cullinan Oncology
CGEM
$1.18B
| $316K | ﹤0.01% |
+30,487
| New | +$275K |
|
|
PPIH
1303
Perma-Pipe International
PPIH
$211M
| $314K | ﹤0.01% |
+10,327
| New | +$283K |
|
1304
GoodRx Holdings
GDRX
$1.25B
| $313K | ﹤0.01% |
+115,584
| New | +$379K |
|
|
VENU
1305
Venu Holding Corp
VENU
$120M
| $313K | ﹤0.01% |
+37,142
| New | +$412K |
|
1306
Lexicon Pharmaceuticals
LXRX
$1.07B
| $309K | ﹤0.01% |
+268,433
| New | +$369K |
|
1307
CALL
Applied Materials
AMAT
$415B
| $309K | ﹤0.01% |
1,200
+700
| +140% | +$168K |
|
1308
Apyx Medical
APYX
$146M
| $305K | ﹤0.01% |
+87,115
| New | +$304K |
|
1309
Ennis
EBF
$558M
| $305K | ﹤0.01% |
16,913
-6,161
| -27% | -$107K |
|
1310
Lineage Cell Therapeutics
LCTX
$286M
| $303K | ﹤0.01% |
+181,694
| New | +$314K |
|
1311
Forte Biosciences
FBRX
$1.57B
| $302K | ﹤0.01% |
+11,084
| New | +$194K |
|
1312
Oaktree Specialty Lending
OCSL
$1.12B
| $301K | ﹤0.01% |
+23,594
| New | +$315K |
|
1313
Ituran Location and Control
ITRN
$1.02B
| $300K | ﹤0.01% |
+6,975
| New | +$274K |
|
1314
Sabre
SABR
$835M
| $296K | ﹤0.01% |
+217,735
| New | +$375K |
|
1315
Colliers International
CIGI
$5.11B
| $294K | ﹤0.01% |
2,000
-4,144
| -67% | -$623K |
|
1316
4D Molecular Therapeutics
FDMT
$582M
| $294K | ﹤0.01% |
+39,175
| New | +$397K |
|
1317
Anixa Biosciences
ANIX
$111M
| $293K | ﹤0.01% |
+93,931
| New | +$385K |
|
1318
Tango Therapeutics
TNGX
$4.51B
| $291K | ﹤0.01% |
32,897
-48,341
| -60% | -$417K |
|
1319
Genesco
GCO
$419M
| $290K | ﹤0.01% |
+11,721
| New | +$336K |
|
1320
ProKidney
PROK
$347M
| $289K | ﹤0.01% |
128,853
+23,924
| +23% | +$62.9K |
|
1321
Riskified
RSKD
$712M
| $287K | ﹤0.01% |
57,723
-6,639
| -10% | -$32K |
|
1322
Nutanix
NTNX
$17.4B
| $283K | ﹤0.01% |
+5,482
| New | +$335K |
|
1323
Rigel Pharmaceuticals
RIGL
$778M
| $282K | ﹤0.01% |
6,582
-9,785
| -60% | -$369K |
|
|
NFBK
1324
DELISTED
Northfield Bancorp
NFBK
| $281K | ﹤0.01% |
24,571
-17,783
| -42% | -$197K |
|
1325
Aura Biosciences
AURA
$796M
| $280K | ﹤0.01% |
51,419
+7,998
| +18% | +$47.5K |
|
Similar funds
LPC
IWC
EIG
IMPI
ZIM
ZIG
ACA
WANY
ExodusPoint Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, ExodusPoint Capital Management held 2,189 positions worth $12.7B, up 30% from $9.79B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
ExodusPoint Capital Management deployed $2.85B of net new capital in Q4 2025, opening 723 new positions and adding to 409 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Procter & Gamble, an estimated $43.7M trimmed.
- ExodusPoint Capital Management's largest Q4 2025 buy was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
- ExodusPoint Capital Management added most to NVIDIA in Q4 2025, an estimated $689M increase.
- ExodusPoint Capital Management's biggest Q4 2025 reduction was Procter & Gamble, cutting an estimated $43.7M.
- ExodusPoint Capital Management fully exited Meta Platforms (Facebook) in Q4 2025, selling an estimated $71.5M.
- ExodusPoint Capital Management's ten largest holdings make up 30% of its $12.7B portfolio in Q4 2025.
- ExodusPoint Capital Management opened 723 new positions and closed 716 in Q4 2025.
- ExodusPoint Capital Management's portfolio value rose 30% quarter-over-quarter to $12.7B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.